

## **CURRICULUM VITAE ET STUDIORUM LUCA MOSCETTI**

Luca Moscetti  
e-mail: [moscetti.luca@aou.mo.it](mailto:moscetti.luca@aou.mo.it)

Medical Degree on July 28<sup>th</sup>, 1994  
Medical license nr 01835, registered in the Italian general medical council since 1995  
Board in Oncology on December 13<sup>th</sup>, 2000  
Language English C1

**1995:** Member of Italian Society of Medical Oncology (AIOM)  
**2002:** National Younger Oncologist Representative for AIOM Lazio section  
**2005-2009:** Councilor of Regional Executive of AIOM Lazio  
**2007:** Member of European Society of Medical Oncology (ESMO)  
**2008-2018** Member of AIOM working group for the medical education  
**2015-17** Councilor of Regional Executive of AIOM Lazio  
**2015-2018** Member of the Board of Directors of Italian group for clinical oncology research (GOIRC)  
**since 2018** Member of the Board of Directors and Treasurer of Italian group for clinical oncology research (GOIRC)  
**since 2017** Member of the Breast International Group (BIG) task force for de novo metastatic luminal breast cancer  
**2019-2020** National expert H-SE-ONC - Oncology, Haematology office , European Medicines Agency (EMA) Amsterdam, the Netherlands  
**2020-2021** Member of the Board of Directors and Secretary of Italian group for clinical oncology research (GOIRC)  
**Since 2021** Secretary Italian Association of Medical Oncology (AIOM) Emilia Romagna  
**2024** Member of the Board of Directors of Italian group for clinical oncology research (GOIRC)  
**2025** Coordinator Italian Association of Medical Oncology (AIOM) Emilia Romagna

### **Since 1993**

Internal student in Medical Oncology Division. Department of Experimental Medicine and Pathology, "La Sapienza" University, Rome. Director Prof. A. Pellegrini.

### **Since November 1994**

Fellowship in Medical Oncology, Department of Experimental Medicine and Pathology, "La Sapienza" University, Rome. Director Prof. A. Pellegrini, 1<sup>st</sup> School in Medical Oncology, (Director Prof. V. Marinozzi).

**April 1995-August 1996**

Medical Officer of Italian Army

**August 1996**

Fellowship in Medical Oncology, Department of Experimental Medicine and Pathology, "La Sapienza" University, Rome., Director Prof. E. Cortesi, 1<sup>st</sup> School in Medical Oncology, (Director Prof. Cesare Bosman).

**October 1997**

Fellowship in Medical Oncology: S Maria Hospital, Terni, Chief: Prof. F. Di Costanzo.

**Since April 2001**

Medical Oncologist at the Medical Oncology Department, Azienda ASL, Ospedale Belcolle, Viterbo, Italy, Director Dott. C. F. Pollera

**Since 7 November 2006 to 15 June 2007**

Chief ad interim of the Medical Oncology Department, Azienda AUSL, Ospedale Belcolle, Viterbo, Italy

**Since 2007** Member of the Breast Cancer Unit of Medical Oncology Department, Azienda AUSL, Ospedale Belcolle, Viterbo, Italy

**April 2010** Attending as Observer in the Breast Cancer Department MD Anderson Cancer Center, Mentor Prof. V. Valero.

**September 2010** Attending as volunteer in the Oncology division of Bugando Medical Center of Mwanza (Tanzania), Director Dr. N, Masalu

**Since 2011** Professional assignment: Breast Cancer Unit of Medical Oncology Department, Azienda AUSL, Ospedale Belcolle, Viterbo, Italy

**June 2013** Attending as Observer in the Breast Cancer Department Memorial Sloan Kettering Cancer Center New York, Mentor Dr M. Fornier.

**Since January 2016** Medical Oncologist at the Medical Oncology Department, AOU Policlinico di Modena - Centro Oncologico Modenese - Via del Pozzo 71 - 41125 Modena – Italy, Breast cancer Unit, Chief G Luppi, Oncology Department Chief. Prof S. Cascinu

**2019-2020** National expert H-SE-ONC - Oncology, Haematology office, European Medicines Agency (EMA) Amsterdam, the Netherlands

**2024** Coordinator Real World Study Board in the Oncology Division, University Hospital Modena, Italy

## Papers

1. Moscetti L, Ramponi S, Villanti P, Maccaglia C, Cortesi E: Atrial fibrillation in a patient with Non Small Cell Lung Cancer during Paclitaxel therapy. *Clinica Terapeutica* 149: 377-379, 1998
2. Moscetti L, Saltarelli R, Giuliani R, Fornarini G, Bezzi M, Cortesi E: Intra arterial liver chemotherapy and hormone therapy in malignant insulinoma: Case report and review of literature. *Tumori*, Vol. 86, N°6, pp 475-479, 2000.
3. Grifalchi F, Padovani A, Romeo F, Trinca C, Moscetti L, Cortesi E: Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. *Tumori* 1, 87: 58-59, 2001.
4. Cortesi E, Ramponi S, Corona M, Moscetti L, Grifalchi F, Oliva A, Lembo A, Gasperoni S, Padovani A: Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. *Lung Cancer* 31, 2001, 271-276
5. M. Zeuli, F. Di Costanzo, A. Sdrobolini, S. Gasperoni, F. P. Paoloni, A. Carpi, L. Moscetti, R. Cherubini, F. Cognetti: Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. *Annals of Oncology* 12: 1737-1741, 2001
6. Nelli F, Naso G, Moscetti L : Weekly vinorelbine and docetaxel as second-line chemotherapy for pre-treated non-small cell lung cancer patients: a phase I-II trial. *Journal of Chemotherapy* 2004; 16(4):392-399.
7. L Moscetti, D. Padalino, E. Capomolla, F. Nelli, CF Pollera: A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin. *J. Exp Clin Cancer Res* 24,1, pp 207-210, 2005
8. Gelibter A, Ceribelli A, Pollera CF, Milella M, Moscetti L, Sperduti I, Cognetti F: Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer. *J Cancer Res Clin Oncol.* 2005 Dec;131(12):783-8. Epub 2005 Nov 15
9. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S: Gemcitabine with or without infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). *British Journal of Cancer* (2005) 93, 185 – 189
10. Felici A, Carlini P, Ruggeri EM, Gamucci T, Pollera CF, Marco SD, Fariello AM, Moscetti L, Gelibter A, Adami E, Sperduti I, Cognetti F.: Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluorouracil

continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study, *Cancer Chemother Pharmacol*. 2005 Jul 5;:1-

11. Moscetti L, Nelli F, Padalino D, Sperduti I, Giannarelli D, Pollera CF: Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. *J Chemother*. 2005 Dec;17(6):685-92
12. Moscetti L, Nelli F, Felici A, Rinaldi M, De Santis S, D'Auria G, Mansueto G, Tonini G, Sperduti I, Pollera CF. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. *Cancer*. 2007 Jan 15;109(2):274-81
13. Cortesi E, Moscetti L, Nelli F, De Marinis F, De Paula U, Bangrazi C, Migliorino MR and Donato V. Induction therapy with paclitaxel and carboplatin followed by hyperfractionated radiotherapy plus weekly concurrent chemotherapy and subsequent consolidation therapy in unresectable locally advanced non-small-cell lung cancer. *Tumori*. 2007 Mar-Apr;93(2):133-7
14. Gamucci T, D'Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, Sperduti I, Moscetti L, Belli F, Meliffi L.: Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. *Br J Cancer*. 2007 Oct 22;97(8):1040-5
15. Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I, Zeuli M, Cortesi E, D'Auria G, Pollera CF: A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities. *Clin Colorectal Cancer*. 2008 Jul;7(4):273-9
16. Cancer Pain Outcome Research Study Group (CPOR SG) Investigators Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group *Br J Cancer*. 2009 May 19;100(10):1566-74. Epub 2009 Apr 28
17. Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Morabito A, Pignata S, Pisano C, Ciccarese G, Porrozzì S, Fatigoni S, Caremoli ER, De Grossi S, Acerboni S, Piazza E, Barni S, Cabiddu M, Schiavon S, Magazu M, Caroti C, Decensi A, Testore F, Bonetti A, Daniele B, Turitto G, Veltri E, Gaion F, Moscetti L, Massidda B, Di Lieto M: Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. *Tumori*. 2009 Nov-Dec;95(6):647-51.
18. Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases. *Ann Oncol*. 2010 Sep;21(9):1926-7

19. Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, Moscetti L, Russillo M, Lanzetta G, Mansueto G, Pace A, Maschio M, Vidiri A, Sperduti I, Cognetti F, Carapella CM.: Brain Metastases From Solid Tumors: Disease Outcome According to Type of Treatment and Therapeutic Resources of the Treating Center. *J Exp Clin Cancer Res*. 2011 Jan 18;30:10
20. Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A. Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non-Small-Cell Lung Cancer With the Absence of Epidermal Growth Factor Receptor Mutations. *Clin Lung Cancer*. 2011 Mar;12(2):138-41. Epub 2011 Apr 11
21. Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferraù F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E: A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. *Cancer Chemother Pharmacol*. 2011 Jul 21. [Epub ahead of print]
22. Moscetti L, Nelli F, Ruggeri EM.: Rhabdomyolysis from erlotinib: a case report *Tumori*. 2011 May-Jun;97(3):415-6
23. Nelli F, Moscetti L, Natoli G, Massari A, D'Auria G, Chilelli M, Fabbri MA, Frittelli P, Ruggeri EM. Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. *Int J Clin Oncol*. 2012 Feb 17. [Epub ahead of print]
24. Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. *BJU Int*. 2012 Feb 24.
25. Di Maio M, Leigh NB, Gallo C, Feld R, Ciardiello F et al: Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2012 Dec;7(12):1830-44.
26. F. Nelli G, Natoli L, Moscetti et al: Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis. *J Chemother*. 2013 Apr;25(2):112-8
27. Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate

gemcitabine for advanced pancreatic cancer. *World J Gastroenterol.* 2013 Jul 28;19(28):4511-9. doi: 10.3748/wjg.v19.i28.4511

28. Garassino MC, Martelli O, Broggin M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. *Lancet Oncol.* 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22
29. Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. *J Cancer Res Clin Oncol.* 2013 Jul;139(7):1229-40.
30. Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I, Franco D, Ruggeri EM. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. *Invest New Drugs.* 2013 Aug;31(4):1035-43. doi: 10.1007/s10637-013-9936-9.
31. Gamucci T, Vaccaro A, Ciancola F, Pizzuti L, Sperduti I, Moscetti L, Longo F, Fabbri MA, Giampaolo MA, Mentuccia L, Di Lauro L, Vici P. Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. *J Cancer Res Clin Oncol.* 2013 May;139(5):853-60. doi: 10.1007/s00432-013-1388-2.
32. De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, Fornarini G, Burattini L, Rosti G, Ferrari V, Moscetti L, Chiuri VE, Luzi Fedeli S, Amadori D, Basso U. Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. *Clin Genitourin Cancer.* 2013 Nov 15. pii: S1558-7673(13)00276-0.
33. De Giorgi U, Rihawi K, Aieta M, Lo Re G, Sava T, Masini C, Baldazzi V, De Vincenzo F, Camerini A, Fornarini G, Burattini L, Rosti G, Moscetti L, Chiuri VE, Luzi Fedeli S, Ferrari V, Scarpi E, Amadori D, Basso U: Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. *J Geriatr Oncol.* 2014 Apr;5(2):156-63
34. Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, Pavese I, Sperduti I, Vaccaro A, Vici P. Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. *J Cancer Res Clin Oncol.* 2013 Nov 29

35. Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. *J Cancer*. 2014 Mar 20;5(5):320-7.
36. Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, Barba M, Marchetti P, Michelotti A, Sperduti I, Gamucci T.: Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. *Breast Cancer Res Treat*. 2014 Oct;147(3):599-607.
37. Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, Gori S, Vici P, Gamucci T, Mauri M, Laudadio L, Nuzzo A, Fabbri MA, Fattoruso SI, Mazzilli L, Grassadonia A, Cianchetti E, Natoli C. Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. *Clin Breast Cancer*. 2015 Apr;15(2):e131-7.
38. Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, Barba M, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D'Onofrio L, Sperduti I, Conti F, Rossi V, Cassano A, Maugeri-Saccà M, Mottolese M, Marchetti P. Triple positive breast cancer: a distinct subtype? *Cancer Treat Rev*. 2015 Feb;41(2):69-76.
39. Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. *Future Oncol*. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. *Lancet*. 2015 May 9;385(9980):1863-72.
40. Moscetti L, Fabbri MA, Sperduti I, Fabrizio N, Frittelli P, Massari A, Pompei L, D'Auria G, Pofi E, Ruggeri EM Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? *Tumori*. 2015 Jun 13, epub ahead of print.
41. Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Brogginì M, Garassino MC; TAILOR trialists: Value of KRAS as

prognostic or predictive marker in NSCLC: results from the TAILOR trial. *Ann Oncol.* 2015 Jul 24. epub ahead of print

42. Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Grassadonia A, Michelotti A, Perracchio L, Pescarmona E, Di Filippo F, Giordano A, Maugeri-Saccà M, Vici P. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated with Eribulin. *J Cell Physiol.* 2015 Oct 9. doi: 10.1002/jcp.25213
43. Puglisi F, Fontanella C, Adami F, Amoroso V, Bianchi GV, Bisagni G, Cocco MR, Danese S, Dottori R, Falci C, Fontana A, Gaion F, Generali D, Giampaolo M, Gianni L, Grassadonia A, Grimaldi G, Malagoli M, Moraca L, Moscetti L, Olmeo NA, Portarena I, Rossi E, Saracchini S, Savastano C, Tarenzi E, Turletti A, Zambetti M, Zanfagnin V, Marchetti P. Current challenges in HER2-positive breast cancer. *Crit Rev Oncol Hematol.* 2015 Oct 31. pii: S1040-8428(15)30065-2. doi: 10.1016/j.critrevonc.2015.10.016
44. Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. *Sci Rep.* 2015 Dec 22;5:18670. doi: 10.1038/srep18670
45. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. *Oncotarget.* 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480
46. Moscetti L, Vici P, Gamucci T, Natoli C, Cortesi E, Marchetti P, Santini D, Giuliani R, Sperduti I, Mauri M, Pizzuti L, Mancini ML, Fabbri MA, Magri V, Iezzi L, Sini V, D'Onofrio L, Mentuccia L, Vaccaro A, Ramponi S, Roma CL, Ruggeri EM. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience. *Breast.* 2016 Oct;29:96-101. doi: 10.1016/j.breast.2016.07.005.
47. Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. A Real-World

Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. *J Cell Physiol.* 2017 Jun;232(6):1571-1578. doi: 10.1002/jcp.25685. Epub 2016 Nov 30.

48. Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N. Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. *Breast.* 2017 Apr;32:79-86. doi: 10.1016/j.breast.2016.12.018. Epub 2017 Jan 5
49. Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N. Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag. *Breast.* 2017 May 16. pii: S0960-9776(17)30451-4. doi: 10.1016/j.breast.2017.05.006
50. Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, Barba M, Ruggeri EM Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. *Oncotarget.* 2017 Apr 20. doi: 10.18632/oncotarget.17262.
51. Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, Barba M, Vici. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant. Results from a real word setting. *Oncotarget.* 2017 Apr 9. doi: 10.18632/oncotarget.16982.
52. Moscetti L, Mentuccia L, Vici P, Quadrini S, Sperduti I, Pizzuti L, Fabbri MA, Vaccaro A, Saccà MM, Barba M, Sergi D, Zampa G, Gamucci T: ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. *Future Oncol.* 2017 Apr 21. doi: 10.2217/fon-2017-0062.
53. Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti E Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. *Oncotarget.* 2017 Mar 18. doi: 10.18632/oncotarget.16373. [Epub ahead of print]
54. Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M,

- Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. *Breast Cancer Res Treat.* 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9.
55. Moscetti L. Are All Patients Truly Hormone Receptor Negative? *J Clin Oncol.* 2017 May 10;35(14):1627. doi: 10.1200/JCO.2016.69.2343. Epub 2017 Jan 17
56. Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. *Breast Cancer Res Treat.* 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9.
57. Grassadonia A, Vici P, Gamucci T, Moscetti L, Pizzuti L, Mentuccia L, Iezzi L, Scognamiglio MT, Zilli M, Giampietro J, Graziano V, Natoli C, Tinari N. Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag. *Breast.* 2017 May 16. pii: S0960-9776(17)30451-4. doi: 10.1016/j.breast.2017.05.006.
58. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Giulia MD, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. Retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *Oncotarget.* 2017 May 25. doi: 10.18632/oncotarget.18176.
59. Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. *Eur J Cancer.* 2017 Jun 15. pii: S0959-8049(17)30961-9. doi: 10.1016/j.ejca.2017.05.010.
60. Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A,

Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. *J Cell Physiol.* 2017 Jul 15. doi: 10.1002/jcp.26103.

61. Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F: Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. *Oncotarget.* 2017 Mar 18;8(38):64481-64489
62. Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? *Future Oncol.* 2017 Dec;13(30):2791-2797.
63. Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. *Cancer Biol Ther.* 2018 Jan 16
64. Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. *Cancer Manag Res.* 2018 Jan 15;10:91-103. doi: 10.2147/CMAR.S146658. eCollection 2018. Review
65. Venturelli M, Guaitoli G, Omarini C, Moscetti L: Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer. *Breast Cancer (Dove Med Press)* 2018; 10: 39–49. Published online 2018 Mar 6. doi: 10.2147/BCTT.S137508
66. Omarini C, Bettelli S, Caprera C, Manfredini S, Caggia F, Guaitoli G, Moscetti L, Toss A, Cortesi L, Kaleci S, Maiorana A, Cascinu S, Conte PF, Piacentini F.. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. *Cancer Biol Ther.* 2018 Aug 1:1-8.
67. Fabi A, Alesini D, Valle E, Moscetti L, Caputo R, Caruso M, Carbognin L, Ciccarese M, La Verde N, Arpino G, Cannita K, Paris I, Santini D, Montemurro F, Russillo M, Ferretti G, Filippelli G, Rossello R, Fabbri A, Zambelli A, Leonardi V, D'Ottavio AM, Nisticò C, Stani S, Giampaglia M, Scandurra G, Catania G,

Malaguti P, Giannarelli D, Cognetti F.T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. *Breast*. 2018 Jul 12;41:137-143.

68. De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. *Lancet Oncol*. 2018 Apr;19(4):474-485.
69. Toss A, Piacentini F, Cortesi L, Artuso L, Bernardis I, Parenti S, Tenedini E, Ficarra G, Maiorana A, Iannone A, Omarini C, Moscetti L, Cristofanilli M, Federico M, Tagliafico E. Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. *Oncotarget*. 2018 Aug 3;9(60):31606-31619.
70. Omarini C, Filieri ME, Bettelli S, Manfredini S, Kaleci S, Caprera C, Nasso C, Barbolini M, Guaitoli G, Moscetti L, Maiorana A, Conte PF, Cascinu S, Piacentini F. Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. *Biomed Res Int*. 2018 Jul 24;2018:3756981
71. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoidi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. *J Cell Physiol*. 2018 Dec 10.
72. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P. A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. *Cancer Biol Ther*. 2018 Nov 7:1-9.

73. Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. *J Cancer Res Clin Oncol*. 2019 Jan 2.
74. Fabi A, Lanzetta G, Vizza E, et al. The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy. *Curr Probl Cancer*. 2019;43(6):100479.
75. Toss A, Venturelli M, Sperduti I, Molinaro E, Isca C, Barbieri E, Piacentini F, Omarini C, Cortesi L, Cascinu S, Moscetti L: First-line treatment for endocrine sensitive bone-only metastatic breast cancer: a systematic review and meta-analysis. *Clin Breast Cancer*. 2019 Jul 24
76. Omarini Claudia, Piacentini Federico, Sperduti Isabella, Barbolini Monica, Isca Chrystel, Toss Angela, Cortesi Laura, Barbieri Elena, Massimo Dominici, Luca Moscetti: Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of Phase II and III randomized clinical trials. submitted
77. Omarini C, Palumbo P, Pecchi A, et al. Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. *Cancer Manag Res*. 2019;11:9563–9569.
78. Toss A, Moscetti L, Cascinu S. Occult breast cancer: the uncommon presentation of a common disease. *Chin Clin Oncol*. 2019;8(S1):S10. doi:10.21037/cco.2019.01.06
79. Krasniqi E, Pizzuti L, Barchiesi G, et al. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence [published online ahead of print, 2020 Jan 15]. *J Cell Physiol*.
80. Pizzuti L, Krasniqi E, Barchiesi G, et al. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. *Int J Cancer*. 2020;146(7):1917–1929.
81. Venturelli M, Toss A, Cortesi L, Gambini A, Andreotti A, Cascinu S, Tazzioli G, Moscetti L. Male mammary myofibroblastoma: Two case reports and brief review of literature. *Mol Clin Oncol*. 2020 Jul;13(1):33-37. doi: 10.3892/mco.2020.2038. Epub 2020 Apr 30. PMID: 32454973; PMCID: PMC7241234.
- 82.

Moscetti L, Hennik P, Bolstad B, et al. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. *ESMO Open*. 2020;5(4):e000856. doi:10.1136/esmoopen-2020-000856

83.

Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficarella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. *J Exp Clin Cancer Res*. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3. PMID: 33302999; PMCID: PMC7731769.

84.

Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. *ESMO Open*. 2020 Dec 16;6(1):100008. doi: 10.1016/j.esmoop.2020.100008. Epub ahead of print. PMID: 33399074.

85.

Orlandi A, Iattoni E, Pizzuti L, Fabbri A, Botticelli A, Di Dio C, Palazzo A, Garufi G, Indelicati G, Alesini D, Carbognin L, Paris I, Vaccaro A, Moscetti L, Fabi A, Magri V, Naso G, Cassano A, Vici P, Giannarelli D, Franceschini G, Marchetti P, Bria E, Tortora G. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series. *J Pers Med*. 2020 Dec 18;10(4):291. doi: 10.3390/jpm10040291. PMID: 33353132; PMCID: PMC7766166.

86.

Nelli F, Fabbri MA, Moscetti L, Sperduti I, Gamucci T, Mansueto G, Carlo S, Cortesi E, Martelli O, Natoli C, Angelini F, Ruggeri EM. Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: a real-world observational cohort study. *Recenti Prog Med*. 2020 Dec;111(12):761-768. doi: 10.1701/3509.34967. PMID: 33362173.

87.

Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, Armocida C, Barbieri E, Cortesi L, Moscetti L, Piacentini F, Omarini C, Andreotti A, Gambini A, Battista R, Dominici M, Tazzioli G. Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront

treatment in the COVID era. *ESMO Open*. 2021 Feb 11;6(2):100055. doi: 10.1016/j.esmoop.2021.100055. Epub ahead of print. PMID: 33582382.

88.

Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). *Clin Cancer Res*. 2021 Mar 30;clincanres.4928.2020. doi: 10.1158/1078-0432.CCR-20-4928. Epub ahead of print. PMID: 33785482.

89.

Krasniqi E, Pizzuti L, Valerio MR, Capomolla E, Botti C, Sanguineti G, Marchetti P, Anselmi E, Tomao S, Giordano A, Ficorella C, Cannita K, Livi L, Meattini I, Mauri M, Greco F, Veltri EM, Michelotti A, Moscetti L, Giotta F, Lorusso V, Paris I, Tomao F, Santini D, Tonini G, Villa A, Gebbia V, Gamucci T, Ciliberto G, Sperduti I, Mazzotta M, Barba M, Vici P. Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. *Int J Med Sci*. 2021 Mar 27;18(10):2245-2250. doi: 10.7150/ijms.54996. PMID: 33859534; PMCID: PMC8040412.

90.

Monari F, Grandi G, Guidotti I, Torcetta F, Battista R, Coluccio V, Piombino C, Moscetti L, Neri I, Toss A. Carboplatin-Paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis. *Minerva Obstet Gynecol*. 2021 May 14. doi: 10.23736/S2724-606X.21.04799-0. Epub ahead of print. PMID: 33988018.

91.

Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioi T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. *Sci Rep*. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z. PMID: 34215766; PMCID: PMC8253801.

92. L. Moscetti, I. Sperduti, A. Frassoldati, A. Musolino, C. Nasso, A. Toss, C. Omarini, M. Dominici, F. Piacentini: Quality of life of therapies for hormone

receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe. *The Breast*.

93. Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. *Ann Oncol*. 2021 Jul 2:S0923-7534(21)02105-0.
94. Harbeck N, Rastogi P, Martin M, and monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol* 2021;32(12):1571-1581. doi:10.1016/j.annonc.2021.09.015
95. Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, Veltri EM, Meattini I, Berardi R, Di Lisa FS, Natoli C, Pistelli M, Iezzi L, Risi E, D'Ostilio N, Tomao S, Ficorella C, Cannita K, Riccardi F, Cassano A, Bria E, Fabbri MA, Mazzotta M, Barchiesi G, Botticelli A, D'Auria G, Ceribelli A, Michelotti A, Russo A, Salimbeni BT, Sarobba G, Giotta F, Paris I, Saltarelli R, Marinelli D, Corsi D, Capomolla EM, Sini V, Moscetti L, Mentuccia L, Tonini G, Raffaele M, Marchetti L, Minelli M, Ruggeri EM, Scavina P, Bacciu O, Salesi N, Livi L, Tinari N, Grassadonia A, Fedele Scinto A, Rossi R, Valerio MR, Landucci E, Stani S, Fratini B, Maugeri-Saccà M, De Tursi M, Maione A, Santini D, Orlandi A, Lorusso V, Cortesi E, Sanguineti G, Pinnarò P, Cappuzzo F, Landi L, Botti C, Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli S, Marchetti P, Ciliberto G, Vici P. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. *Ther Adv Med Oncol*. 2021 Nov 29;13:17588359211059873. doi: 10.1177/17588359211059873.
96. Canino F, Omarini C, Cerma K, Moscetti L, Tornincasa A, Trudu L, Dominici M, Piacentini F. Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. *Clin Breast Cancer*. 2022 Feb 7:S1526-8209(22)00036-2. doi: 10.1016/j.clbc.2022.02.002. Epub ahead of print. PMID: 35246390
97. Omarini, C., Piacentini, F., Sperduti, I., Cerma, K., Barbolini, M., Canino, F., Nasso, C., Isca, C., Caggia, F., Dominici, M., & Moscetti, L. (2022). T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. *BMC cancer*, 22(1), 623.
98. Canino, F., Piacentini, F., Omarini, C., Toss, A., Barbolini, M., Vici, P., Dominici, M., & Moscetti, L. (2022). Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. *International journal of molecular sciences*, 23(13), 7079.

99. Del Mastro L, Poggio F, Blondeaux E, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. *Lancet Oncol.* 2022;23(12):1571-1582.
100. Ligorio F., Di Cosimo, S., Verderio, P., Ciniselli, C. M., Pizzamiglio, S., Castagnoli, L., Dugo, M., Galbardi, B., Salgado, R., Loi, S., Michiels, S., Triulzi, T., Tagliabue, E., El-Abed, S., Izquierdo, M., de Azambuja, E., Nuciforo, P., Huober, J., Moscetti, L., Janni, W., Vernieri, C. (2022). Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. *Journal of the National Cancer Institute*, 114(12), 1720–1727.
101. Toss, A., Venturelli, M., Civallero, M., Piombino, C., Domati, F., Ficarra, G., Combi, F., Cabitza, E., Caggia, F., Barbieri, E., Barbolini, M., Moscetti, L., Omarini, C., Piacentini, F., Tazzioli, G., Dominici, M., & Cortesi, L. (2022). Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. *Frontiers in oncology*, 12, 1016295.
102. Cerma, K., Piacentini, F., Moscetti, L., Barbolini, M., Canino, F., Tornincasa, A., Caggia, F., Cerri, S., Molinaro, A., Dominici, M., & Omarini, C. (2023). Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. *Biomedicines*, 11(1),
103. Toss A., Moscetti L.: Are you treating ypno patient with adjuvant abemaciclib? *ESMO Open* 8 , Issue 3 - 2023 Published online: April 18, 2023
104. Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neoppearl nationwide collaborative study. *Front Oncol.* 2023 Jun 27;13:1177681
105. Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, Giarratano T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, Vernieri C, Curigliano G. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. *Eur J Cancer.* 2023 Jun 20;190:112944.
106. Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, Borella F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S, Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O, Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M, Berardi

R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME, Zustovich F, Cappuzzo F, Landi L, Torrisci R, Scagnoli S, Botticelli A, Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L, Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM, Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A, De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G, Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G, Vici P. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study. *Front Oncol.* 2023 May 16;13:1152123.

107. D'Onofrio R, Omarini C, Toss A, Sperduti I, Piacentini F, Barbolini M, Cortesi L, Barbieri E, Pettorelli E, Chiavelli C, Dominici M, Moscetti L. Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting. *Clin Breast Cancer.* 2023 Jul 7:S1526-8209(23)00170-2.
108. D'Onofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, Cortesi L, Barbieri E, Canino F, Dominici M, Moscetti L. Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis. *Clin Breast Cancer.* 2023 Sep 9:S1526-8209(23)00218-5.
109. Toss A, Ponzoni O, Riccò B, Piombino C, Moscetti L, Combi F, Palma E, Papi S, Tenedini E, Tazzioli G, Dominici M, Cortesi L. Management of PALB2-associated breast cancer: A literature review and case report. *Clin Case Rep.* 2023 Aug 22;11(8):e7747.
110. Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, Omarini C, Toss A, Tamburrano F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F. Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients. *Int J Mol Sci.* 2024 Feb 20;25(5):2490. doi: 10.3390/ijms25052490.
111. Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, Gianni L, Maestri A, Minichillo S, Moscetti L, Mura A, Nicoletti SVL, Omarini C, Pagani R, Sarti S, Toss A, Zamagni C, Cuoghi Costantini R, Caggia F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F. Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPower study. *BMC Cancer.* 2024 Jun 15;24(1):735. doi: 10.1186/s12885-024-12506-0. PMID: 38879498; PMCID: PMC11179289.

112. Krasniqi E, Ercolani C, Di Benedetto A, Di Lisa FS, Filomeno L, Arcuri T, Botti C, Pelle F, Cavicchi F, Cappelli S, Barba M, Pizzuti L, Maugeri-Saccà M, Moscetti L, Grassadonia A, Tinari N, Sanguineti G, Takanen S, Fragnito D, Terrenato I, Buglioni S, Perracchio L, Latorre A, De Maria R, Pallocca M, Ciliberto G, Giotta F, Vici P. DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study. *Cancers (Basel)*. 2024 Jul 23;16(15):2628. doi: 10.3390/cancers16152628. PMID: 39123356; PMCID: PMC11311544.
113. de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. *ESMO Open*. 2024 Oct 16;9(11):103938. doi: 10.1016/j.esmoop.2024.103938. Epub ahead of print. PMID: 39418883; PMCID: PMC11532431.
114. Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America (European Health Data & Evidence Network) submitted.
115. Michail Ignatiadis, MD\*; Andrew Bailey, MSc\*; Heather McArthur, MD\*; Sarra El-abed, MD; Evandro de Azambuja, MD; Otto Metzger, MD; Stephen Y. Chui, MD; Max Dieterich, MD; Thomas Perretti, MSc; Esther Shearer-Kang, PhD; Luciana Molinero, PhD; Günther G. Steger, MD; Jacek Jassem, MD, Soo Chin Lee, MD; Michaela Higgins, MD; Jose Zarba, MD; Marcus Schmidt, MD; Henry Gomez, MD; Angel Guerrero Zotano, MD; Luca Moscetti, MD; Joanne Chiu, MD; Elisabetta Munzone, MD; Noa Efrat Ben-Baruch, MD; Emilio Bajetta, MD; Shinji Ohno, MD; Seock-Ah Im, MD; Gustavo Werutsky, MD; Einav Nili Gal-Yam, MD; Xavier Gonzalez Farre, MD; Ling-Ming Tseng, MD; William Jacot, MD; Oleg Gluz, MD; Zhimin Shao, MD; Yaroslav Shparyk, MD; Anastasia Zimina, MD; Eric Winer, MD; David A. Cameron, MD; Giuseppe Viale, MD; Shigehira Saji, MD†; Richard Gelber, PhD†; Martine Piccart, MD†; Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: Final Results of the ALEXANDRA/IMpassion030 Randomized Clinical Trial JAMA 2024 , accepted
116. Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L; EUROPA Trial Investigators. Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority,

randomised trial. *Lancet Oncol.* 2024 Dec 11:S1470-2045(24)00661-2. doi: 10.1016/S1470-2045(24)00661-2. PMID: 39675376.

117. Pellegrino B, Giovanardi F, Tibaldi C, Moscetti L, Vingiani A, Calabrò L, Zoppoli G, Didone S, Ferrando L, Franceschi E, Todeschini R, Tognetto M, Leonetti A, Minari R, Tommasi C, Serra O, Boni L, Pruneri G, Musolino A. Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). *Tumori.* 2024 Dec 15:3008916241302919. doi: 10.1177/03008916241302919. PMID: 39676332.
118. Krasniqi E, Filomeno L, Arcuri T, Di Lisa FS, Astone A, Cutigni C, Foglietta J, Nunzi M, Rossi R, Minelli M, Meattini I, Visani L, Scialino J, Livi L, Moscetti L, Marchetti P, Botticelli A, Paris I, Pavese F, D'Angelo T, Sini V, Stani S, Valerio MR, Grassadonia A, Tinari N, Mazzotta M, Vergati M, D'Auria G, Gamucci T, D'Onofrio L, Gasparro S, Roselli A, Fulvi A, Ferretti G, Torchia A, Giordano M, Greco F, Pantano F, Tonini G, Fabbri A, Bria E, Garufi G, Fiorio E, Raffaele M, Pistelli M, Berardi R, Saltarelli R, Kayal R, Ferranti FR, Cannita K, Irelli A, D'Ostilio N, De Rossi C, Palumbo R, Cariello A, Sanguineti G, Calabrò F, Pizzuti L, Barba M, Botti C, Pelle F, Cappelli S, Cavicchi F, Puccica I, Villanucci A, Sperduti I, Ciliberto G, Vici P. Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study. *Cancers (Basel).* 2024 Dec 7;16(23):4104. doi: 10.3390/cancers16234104. PMID: 39682290; PMCID: PMC11639934.
119. Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L, Steger GG, Jassem J, Lee SC, Higgins M, Zarba J, Schmidt M, Gomez H, Guerrero Zotano A, Moscetti L, Chiu J, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam EN, Gonzalez Farre X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Zimina A, Winer E, Cameron DA, Viale G, Saji S, Gelber R, Piccart M. Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial. *JAMA.* 2025 Jan 30:e2426886. doi: 10.1001/jama.2024.26886. Epub ahead of print. PMID: 39883436; PMCID: PMC11783246.
120. Moscetti L, Barbieri E, Zattarin E, Vici P, Zoppoli G, Musolino A, Natalizio S, Canino F, Ravera F, Filomeno L, Arcuri T, Omarini C, Piacentini F, Barbolini M, Cortesi L, Caggia F, Civallero M, Dominici M, Toss A: Time to next treatment to evaluate the therapeutic sequence after first or second line CDK4/6 inhibitors of hormone receptor positive, Her-2 negative, advanced breast cancer in Italy. Retrospective/prospective observational trial. In press, *Esmo real world data and digital oncology*, Volume 8 - Issue C - 2025
121. Krasniqi E, Filomeno L, Arcuri T, Ferretti G, Gasparro S, Fulvi A, Roselli A, D'Onofrio L, Pizzuti L, Barba M, Maugeri-Saccà M, Botti C, Graziano F, Puccica I, Cappelli S, Pelle F, Cavicchi F, Villanucci A, Paris I, Calabrò F, Rea S, Costantini M, Perracchio L, Sanguineti G, Takanen S, Marucci L, Greco L, Kayal R, Moscetti

L, Marchesini E, Calonaci N, Blandino G, Caravagna G, Vici P. Multimodal deep learning for predicting neoadjuvant treatment outcomes in breast cancer: a systematic review. *Biol Direct*. 2025 Jun 23;20(1):72. doi: 10.1186/s13062-025-00661-8. PMID: 40551237; PMCID: PMC12183913.

122. Zattarin, E., Moscetti, L., D'Agostino, E., Bertolotti, A., Sperduti, I., Chiavelli, C., Canino, F., Piacentini, F., Cortesi, L., Dominici, M., & Toss, A. (2025). Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade. *JCO global oncology*, 11, e2500139. <https://doi.org/10.1200/GO-25-00139>
123. Pineda-Moncusí M, Rekkas A, Martínez Pérez Á, Leis A, Lopez Gomez C, Fey E, Bruninx E, Maljković F, Sánchez-Sáez F, Rodeiro-Boliart J, Zsuzsa Kiss L, Franz M, Mayer MA, Eleangovan N, Pulido PP, Natsiavas P, Şen S, Cooper S, Reisberg S, Manlik K, Price DB, Moscetti L, Merkelbach M, Tadrous M, Rappoport N, Claire R, Garcia-Torrens S, Prieto-Alhambra D, Rijnbeek PR, Burkard T; Drug Shortages EHDEN Study Group. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. *Lancet Public Health*. 2025 Oct;10(10):e835-e847. doi: 10.1016/S2468-2667(25)00194-X. PMID: 40992879.
124. Toss A, Zattarin E, Moscetti L, Dominici M. Bridging language barriers in global oncology: toward more inclusive scientific communication. *ESMO Open*. 2025 Dec;10(12):105911. doi: 10.1016/j.esmoop.2025.105911. Epub 2025 Nov 18. PMID: 41259898; PMCID: PMC12670554.
125. Ferro A, Atzori F, Angiolini C, Bortolin M, Cortesi L, Fabi A, Fiorio E, Garrone O, Gianni L, Giordano M, Merlini L, Mion M, Moscetti L, Sartori D, Sarobba MG, Spazzapan S, Lusardi R, Piras EM; DonnaRosa Group. *DonnaRosa* Project: Exploring Informal Communication Practices Among Breast Cancer Specialists. *Curr Oncol*. 2025 Dec 14;32(12):704. doi: 10.3390/currncol32120704. PMID: 41440232; PMCID: PMC12731300.

### Didactics

C.F. Pollera, L. Moscetti: Le metastasi cerebrali dalla biologia alle nuove prospettive terapeutiche: nuovi approcci terapeutici. *Didactic's book chapter for "Corso residenziale Accademia Nazionale di Medicina, Sezione di Neuroscienze Cliniche*. Rome June 22, 2001."

University lesson "*Clinical trial in Oncology*", University "la Sapienza", School of Medicine, Rome October 23, 2001. Chief Prof. G. Naso,

University lesson "*Clinical trial in Oncology*", University "la Sapienza", School of Medicine. Rome, November 12, 2001. Chief Prof. E. Cortesi.

2008-2012: Chair of Medical Oncology, Nurse Degree University Tor Vergata Rome.

2012 to 2015: Chair of Medical Oncology, Degree course of Techniques in Medical Radiology, Imaging and Radiotherapy University La Sapienza Rome

2024 Adjunct Professor course of study of the specialization school in Medical Oncology: Breast neoplasms and clinical trials (MED06) at the University of Modena and Reggio Emilia

#### Books Chapters

1. Cortesi E, **Moscetti L**: Assistenza Domiciliare, in "Oncologia Medica Pratica", editor: M Lopez. Pag 1457-61, Società Editrice Universo, 2000.
2. Padovani A, **Moscetti L**, Pellegrini A: Fisiopatologia ed endocrinoterapia dei tumori ormono-dipendenti. Chapter 106 in "Trattato di Chirurgia Oncologica", editors: F. Mazzeo, P. Forestieri, Piccin, 2002.
3. Padovani A, **Moscetti L**, Pellegrini A: Fisiopatologia ed endocrinoterapia dei tumori ormono-dipendenti. Chapter 26 in "Trattato di Clinica e Terapia Chirurgica", editors: F. Mazzeo, P. Forestieri, Piccin, 2002.
4. Pollera C.F., **Moscetti L**: Il trattamento dei pazienti con neoplasia della vescica. Chapter 4 in "Oncologia geriatrica 3", editor: V. Zagonel, Il Pensiero Scientifico, 2003.
5. **L. Moscetti**, F. Nelli: Non small cell lung cancer with brain metastases, platinum based chemotherapy in: Methods of cancer diagnosis, therapy and prognosis, volume 2, lung cancer: editor M.A. Hayat, Springer 2008.

#### Recent participation to clinical trials

*Certified experience in conducting clinical trials in good clinical practice*

Principal Investigator in the following field of oncology research

- *Recurrent and early breast cancer: phase II, III and IV trials*
- *Advanced and locally advanced Lung cancer: phase II, III and IV trials.*
- *Bladder cancer: adjuvant and metastatic setting, phase II and III trials.*
- *Colorectal cancer and pancreatic cancer phase II and III trials.*
- *Ovarian cancer: phase III trials.*
- *Pain in oncology: phase II trial.*
- *Anemia, phase III trial.*

Member of the steering committee of Impassion 030 study

Member of the steering committee of NEO-ALTTO trial  
Member of the BIG task for de novo luminal metastatic breast cancer  
Member of the steering committee of evERA study ML43171

2015 Scientific Board Journal clinical oncology italian version  
2023 Editorial Board Member Clinical Oncology, Scientific Reports (Springer Nature)  
2024 Editorial Review Board Breast Cancer: Basic and Clinical Research (Sage)  
2023 Editorial Board Member Precision Cancer Medicine (Ame)  
2022 International Advisory Review Board Cancer Treatment and Research Communications, Breast Cancer (Elsevier)  
2021 Guest Editor Special Issue Editor: The Endocrine Basis of Breast Cancer, Cancers 2022, 14(2)

#### **Participation to international network**

2023 Associated to the European Health Data & Evidence Network (EHDEN, <https://www.ehden.eu/>)  
2024 Associated to Darwin EU (<https://www.darwin-eu.org/>) A EU network for real world evidences.  
2025 Member ENCePP, WG on Real-World-Data (RWD) sources in non-interventional studies

I authorize the processing of personal data (Italian law D.Lgs. 196/03 and Art. 13 GDPR 679)

*Modena, January 8<sup>th</sup> 2026*